Latest research on BMS-477118

Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

Latest findings

We found that a review for one drug in COPD (Arcapta Neohaler) mentioned a MID and reviews for 12 drugs in diabetes (Avandaryl, Symlin, Duetact, Exubera, Januvia, BYETTA, Cycloset, Onglyza, Kombiglyze XR, Victoza, Tradjenta and Bydureon) mentioned a threshold (number of patients achieving the target haemoglobin A1C level) that is linked to patient-centred outcomes. [source, 2015]
Saxagliptin, from Bristol-Myers Squibb, was approved by the FDA in 2009 and marketed as Onglyza and is another DPP-4 potent inhibitor with pharmacokinetic and pharmacodynamic properties suitable for once-daily dosing, with or without food, at any time of the day [195, 196]. [source, 2015]
Its commercial name is Onglyza (Bristol-Myers Squibb, New York, NY, USA; AstraZeneca, London, UK) and it is on the market as an immediate-release, film-coated tablet containing 5 mg SAXA, supplied in alu/alu blister packaging. [source, 2014]
Saxagliptin (BMS-477118) is a potent inhibitor of DPP4 that is approximately 10-fold more potent than Vildagliptin or sitagliptin. [source, 2012]
Saxagliptin (Onglyza©, BMS-477118, or (1 S,3 S,5 S)-2-[(2 S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohydrate [13], Vildagliptin [27], sitagliptin [28], active and DPP4 cleaved glucagon-like-peptide-1 (GLP-17-36 and GLP-19-36, respectively) were synthesized at Bristol-Myers Squibb. [source, 2012]
Several DPP-4 inhibitors have been produced [66, 67], and they include vildagliptin (1) (LAF237) marketed as Galvus, by Novartis; sitagliptin (2) (MK-0431) sold as Januvia by Merck and saxagliptin (3) (BMS-477118, a product of Bristol-Myers Squibb, that competitively and reversibly inhibit the enzyme, DPP-4 [68-70]. [source, 2011]